Insider Heat: What after Richard Reese’s Insider Unload of Charles River Laboratories Intl. Inc (NYSE:CRL) Stock?

November 29, 2016 - By Ellis Scott

Insider Heat: What after Richard Reese's Insider Unload of Charles River Laboratories Intl. Inc (NYSE:CRL) Stock?

Richard Reese Insider Sell

The director of Charles River Laboratories International Inc, Richard Reese, has just sold – 4,539 shares of the corporation he’s operating – coming to an aggregate sell of $326,485 US Dollars (this based on avg stock price of $71.9). Currently, Mr. Richard, owns 40,404 shares, which accounts for 0.09% of Charles River Laboratories International Inc’s market cap.

Charles River Laboratories Intl. Inc (NYSE:CRL) Ratings Coverage

Out of 10 analysts covering Charles River Laboratories (NYSE:CRL), 4 rate it a “Buy”, 3 “Sell”, while 3 “Hold”. This means 40% are positive. $100 is the highest target while $65 is the lowest. The $82.88 average target is 15.82% above today’s ($71.56) stock price. Charles River Laboratories has been the topic of 18 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The stock of Charles River Laboratories Intl. Inc (NYSE:CRL) has “Neutral” rating given on Tuesday, June 21 by Credit Suisse. Citigroup maintained Charles River Laboratories Intl. Inc (NYSE:CRL) on Thursday, August 4 with “Neutral” rating. Barclays Capital maintained Charles River Laboratories Intl. Inc (NYSE:CRL) on Friday, May 20 with “Underweight” rating. The stock of Charles River Laboratories Intl. Inc (NYSE:CRL) has “Outperform” rating given on Friday, January 8 by Robert W. Baird. Wells Fargo upgraded the stock to “Outperform” rating in Thursday, January 7 report. The firm earned “Buy” rating on Friday, January 8 by Jefferies. Jefferies maintained it with “Buy” rating and $100 target price in Thursday, August 4 report. As per Friday, August 28, the company rating was maintained by William Blair. The firm earned “Hold” rating on Friday, July 31 by Deutsche Bank. The rating was downgraded by UBS to “Sell” on Tuesday, September 6.

Insitutional Activity: The institutional sentiment decreased to 0.95 in Q2 2016. Its down 0.48, from 1.43 in 2016Q1. The ratio dropped, as 25 funds sold all Charles River Laboratories Intl. Inc shares owned while 81 reduced positions. 39 funds bought stakes while 113 increased positions. They now own 44.08 million shares or 4.37% less from 46.09 million shares in 2016Q1.

The Quebec – Canada-based Van Berkom And Associates has invested 2.5% in Charles River Laboratories Intl. Inc (NYSE:CRL). Redmile Grp Limited Liability Co has 131,606 shares for 1.04% of their US portfolio. Pacad Invest has 0.04% invested in the company for 3,100 shares. Neuberger Berman Grp Ltd Liability holds 877,913 shares or 0.1% of its portfolio. Redwood Invs Limited Liability Corp holds 175,800 shares or 1.33% of its portfolio. Cardinal, a North Carolina-based fund reported 5,637 shares. The Maryland-based Price T Rowe Assoc Incorporated Md has invested 0% in Charles River Laboratories Intl. Inc (NYSE:CRL). Signaturefd Ltd Limited Liability Company holds 0% or 20 shares in its portfolio. Leavell Invest Management last reported 0.05% of its portfolio in the stock. Shell Asset Management has invested 0.06% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL). Channing Cap Management Ltd Liability Co owns 685,581 shares or 2.37% of their US portfolio. Cubist Systematic Strategies Llc last reported 5,776 shares in the company. Eagle Boston Investment Incorporated has 0.89% invested in the company for 79,713 shares. Victory owns 433,163 shares or 0.14% of their US portfolio. Endurant Mgmt L P accumulated 1.1% or 40,088 shares.

Insider Transactions: Since July 1, 2016, the stock had 0 insider purchases, and 6 selling transactions for $4.42 million net activity. 7,877 Charles River Laboratories Intl. Inc (NYSE:CRL) shares with value of $662,446 were sold by Molho Davide. 18,351 Charles River Laboratories Intl. Inc (NYSE:CRL) shares with value of $1.57 million were sold by FOSTER JAMES C. The insider MASSARO GEORGE sold $310,750. Another trade for 7,740 shares valued at $681,120 was sold by WALLMAN RICHARD F.

The stock closed at $71.56 during the last session. It is down 12.20% since April 26, 2016 and is downtrending. It has underperformed by 17.46% the S&P500.

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The company has a market cap of $3.36 billion. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. It has a 24.02 P/E ratio. The Firm operates through three divisions: Research Models and Services , which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

According to Zacks Investment Research, “Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years.”

Analysts await Charles River Laboratories Intl. Inc (NYSE:CRL) to report earnings on February, 8. They expect $1.12 EPS, up 12.00% or $0.12 from last year’s $1 per share. CRL’s profit will be $52.59 million for 15.97 P/E if the $1.12 EPS becomes a reality. After $1.18 actual EPS reported by Charles River Laboratories Intl. Inc for the previous quarter, Wall Street now forecasts -5.08% negative EPS growth.

More recent Charles River Laboratories Intl. Inc (NYSE:CRL) news were published by: Barrons.com which released: “Micron Tech Insiders Sell $5.7 Million in Stock” on October 08, 2014. Also Cnbc.com published the news titled: “Cramer Remix: I can’t believe this stock is a buy” on August 11, 2015. Themiddlemarket.com‘s news article titled: “Mid-Market M&A Dropped Again in April” with publication date: May 03, 2016 was also an interesting one.

CRL Company Profile

Charles River Laboratories International, Inc., incorporated on February 3, 1994, is a full service, early-stage contract research company. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Firm operates through three divisions: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development. It also provides a suite of services and products to support its clients’ manufacturing activities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>